drugset / Trial / NCT00143364

A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo and Zyban for Smoking Cessation

NCT00143364

Phase 3 Completed 1005 enrolled Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary purpose of this study is to evaluate the safety and efficacy of varenicline given for a twelve week treatment period in comparison with placebo and Zyban for smoking cessation.

Timeline

Start
2003-06
Primary completion
Completion
2005-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Varenicline Small molecule

Indications

No indication recorded.